BC Week In Review | Mar 30, 2015
Clinical News

Geodon ziprasidone: Phase III started

RaQualia said Meiji Seika began a double-blind, placebo-controlled, Japanese Phase III trial to evaluate 40, 60 and 80 mg oral ziprasidone twice daily for 6 weeks in about 400 patients. Pfizer markets the product in...
BC Week In Review | Feb 2, 2015
Clinical News

Geodon ziprasidone regulatory update

Geodon is approved in the U.S. to treat schizophrenia, for acute treatment of bipolar manic or mixed episodes, for maintenance treatment of bipolar disorder and for acute agitation in schizophrenic patients. RaQualia has Japanese rights...
BC Week In Review | Mar 12, 2012
Company News

Dr. Reddy's, Pfizer sales and marketing update

Dr. Reddy's launched a generic version of Pfizer's Geodon ziprasidone in the U.S. to treat bipolar disorder, depression and schizophrenia. The small molecule that agonizes or antagonizes multiple neurotransmitter receptors will be available in 20,...
BC Extra | Jul 21, 2011
Financial News

RaQualia off in trading debut

RaQualia Pharma Inc. (Osaka:4579) was off Y100 to Y1,500 Wednesday in its first day of trading on the JASDAQ Growth Market of the Osaka Securities Exchange. This month, the company raised Y6.4 billion ($79.4 million)...
BioCentury | Jul 18, 2011

RaQualia scores

RaQualia scores In one of the largest biotech IPOs ever in Japan, RaQualia Pharma Inc. last week raised ¥6.4 billion ($79.4 million), giving it a post-money valuation of ¥21.5 billion ($266.6 million) and putting its...
BC Extra | Jul 13, 2011
Top Story

RaQualia raises $79.4M in IPO

RaQualia Pharma Inc. (Aichi, Japan) raised Y6.4 billion ($79.4 million) through the sale of 4 million shares at Y1,600 in an IPO underwritten by Daiwa Securities and 12 other securities firms. The shares are expected...
BioCentury | Jun 20, 2011

Reprise for RaQualia

Japan's RaQualia Pharma Inc. revived its IPO plans and now expects to go public next month with an enlarged deal. The plans had been on hold since the Japanese earthquake and tsunami in March. The...
BC Extra | Jun 17, 2011
Financial News

RaQualia resumes IPO plans

RaQualia Pharma Inc. (Aichi, Japan) plans to sell 4 million shares in an IPO underwritten by Daiwa Securities and 12 other securities firms. The shares have been approved for listing on the JASDAQ Growth Market...
BC Week In Review | Apr 11, 2011
Clinical News

Abilify aripiprazole neurology data

The U.S. Department of Health and Human Service's Agency for Healthcare Research and Quality (AHRQ) released a draft comparative effectiveness review of off-label use of atypical antipsychotics showing that off-label use of Abilify aripiprazole, Zyprexa...
BC Week In Review | Mar 28, 2011
Clinical News

Abilify aripiprazole regulatory update

FDA issued an alert to healthcare professionals and consumers that the use of certain prescription antipsychotic drugs by women who are pregnant or planning to become pregnant can harm newborns. The agency said the drugs...
Items per page:
1 - 10 of 59